The FDA reopened the comment period on its proposed rule for direct-to-consumer marketing of prescription drugs. The decision follows the release of an agency-sponsored study that assessed the impact of distracting images or statements in ads on consumers' understanding of information about drug risks and benefits.

Full Story:

Related Summaries